Skip to content

Study · Systematic review · 2026

15 results

Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.

Yaseen M, Ameer A, Ali Z, Jamali JA, Kumar A, Basit Ali Siddiqui M, Kumari P, Hassaan M, Nanwani P, Abdul Basit M, Lohana N, Qureshi R, Tesfaye M

Annals of medicine and surgery (2012)13 Jul 2026

PMID42583410 (opens in a new tab)PMCIDPMC13461105 (opens in a new tab)DOI10.1097/ms9.0000000000005353 (opens in a new tab)PepBankPUB-42583410
Read at sourcePubMedAsk about this study
Jump to 15 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study15

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with overweight or obesity, cagrilintide monotherapy significantly reduced body weight versus placebo in a meta-analysis of randomized trials.

    In plain wordsIn adults with overweight or obesity, cagrilintide alone lowered body weight more than placebo in a pooled analysis of trials.

    Peptide
    Cagrilintide
    Outcome
    DecreaseBody weight change with cagrilintide monotherapy
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Mean difference, body weight
    −6.08%
    cagrilintide monotherapy
    Mean difference, body weight
    −5.89 kg
    cagrilintide monotherapy

    Source sentences

    Summary
    Cagrilintide monotherapy produced significant reductions in body weight (MD: -6.08%; MD: -5.89 kg)
    1 context sentence
    Summary · context
    Eligible randomized controlled trials (RCTs) assessed Cagrilintide monotherapy or CagriSema versus placebo.
  2. 02HumanSystematic reviewEfficacy outcome

    In adults with overweight or obesity, cagrilintide monotherapy significantly reduced blood pressure versus placebo.

    In plain wordsIn adults with overweight or obesity, cagrilintide alone lowered blood pressure more than placebo in a pooled analysis of trials.

    Peptide
    Cagrilintide
    Outcome
    DecreaseBlood pressure with cagrilintide monotherapy
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Cagrilintide monotherapy produced significant reductions in body weight (MD: -6.08%; MD: -5.89 kg) and blood pressure, without meaningful HbA1c improvement.
    1 context sentence
    Summary · context
    Eligible randomized controlled trials (RCTs) assessed Cagrilintide monotherapy or CagriSema versus placebo.
  3. 03HumanSystematic reviewEfficacy outcome

    In adults with overweight or obesity, cagrilintide monotherapy produced no meaningful HbA1c improvement versus placebo.

    In plain wordsIn adults with overweight or obesity, cagrilintide alone did not improve HbA1c in a meaningful way compared with placebo.

    Peptide
    Cagrilintide
    Outcome
    No significant changeHbA1c with cagrilintide monotherapy
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Cagrilintide monotherapy produced significant reductions in body weight (MD: -6.08%; MD: -5.89 kg) and blood pressure, without meaningful HbA1c improvement.
    1 context sentence
    Summary · context
    Eligible randomized controlled trials (RCTs) assessed Cagrilintide monotherapy or CagriSema versus placebo.
  4. 04HumanSystematic reviewSafety outcome

    In adults with overweight or obesity, cagrilintide monotherapy modestly but significantly increased adverse events versus placebo.

    In plain wordsIn adults with overweight or obesity, cagrilintide alone caused slightly more side effects than placebo in a pooled analysis.

    Peptide
    Cagrilintide
    Outcome
    IncreaseAdverse events with cagrilintide monotherapy
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both treatments showed modest but statistically significant increases in adverse events.
    1 context sentence
    Summary · context
    Eligible randomized controlled trials (RCTs) assessed Cagrilintide monotherapy or CagriSema versus placebo.

Studies that did not test the peptide alone11

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 05HumanNot a test of Cagrilintide aloneSystematic reviewEfficacy outcome

    In adults with overweight or obesity, CagriSema significantly reduced body weight versus placebo in a meta-analysis of randomized trials.

    In plain wordsIn adults with overweight or obesity, CagriSema lowered body weight more than placebo in a pooled analysis of trials.

    Peptide
    Cagrilintide
    Outcome
    DecreaseBody weight change with CagriSema
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Mean difference, body weight
    −5.98%
    CagriSema
    Mean difference, body weight
    −4.68 kg
    CagriSema

    Source sentences

    Summary
    CagriSema significantly reduced body weight (MD: -5.98%; MD: -4.68 kg)
    1 context sentence
    Summary · context
    Eligible randomized controlled trials (RCTs) assessed Cagrilintide monotherapy or CagriSema versus placebo.

    In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.

  2. 06HumanNot a test of Cagrilintide aloneSystematic reviewEfficacy outcome

    In adults with overweight or obesity, CagriSema significantly reduced waist circumference versus placebo.

    In plain wordsIn adults with overweight or obesity, CagriSema reduced waist size more than placebo in a pooled analysis of trials.

    Peptide
    Cagrilintide
    Outcome
    DecreaseWaist circumference with CagriSema
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Mean difference, waist circumference
    −10.91 cm
    CagriSema

    Source sentences

    Summary
    CagriSema significantly reduced body weight (MD: -5.98%; MD: -4.68 kg), waist circumference (MD: -10.91 cm)
    1 context sentence
    Summary · context
    Eligible randomized controlled trials (RCTs) assessed Cagrilintide monotherapy or CagriSema versus placebo.

    In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.

  3. 07HumanNot a test of Cagrilintide aloneSystematic reviewEfficacy outcome

    In adults with overweight or obesity, CagriSema significantly reduced systolic blood pressure versus placebo.

    In plain wordsIn adults with overweight or obesity, CagriSema lowered the upper blood pressure value more than placebo in a pooled analysis.

    Peptide
    Cagrilintide
    Outcome
    DecreaseSystolic blood pressure with CagriSema
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular

    Source sentences

    Summary
    CagriSema significantly reduced body weight (MD: -5.98%; MD: -4.68 kg), waist circumference (MD: -10.91 cm), systolic blood pressure, and HbA1c.
    1 context sentence
    Summary · context
    Eligible randomized controlled trials (RCTs) assessed Cagrilintide monotherapy or CagriSema versus placebo.

    In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.

  4. 08HumanNot a test of Cagrilintide aloneSystematic reviewEfficacy outcome

    In adults with overweight or obesity, CagriSema significantly reduced HbA1c versus placebo.

    In plain wordsIn adults with overweight or obesity, CagriSema lowered HbA1c more than placebo in a pooled analysis of trials.

    Peptide
    Cagrilintide
    Outcome
    DecreaseHbA1c with CagriSema
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    CagriSema significantly reduced body weight (MD: -5.98%; MD: -4.68 kg), waist circumference (MD: -10.91 cm), systolic blood pressure, and HbA1c.
    1 context sentence
    Summary · context
    Eligible randomized controlled trials (RCTs) assessed Cagrilintide monotherapy or CagriSema versus placebo.

    In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.

  5. 09HumanNot a test of Cagrilintide aloneSystematic reviewSafety outcome

    In adults with overweight or obesity, CagriSema modestly but significantly increased adverse events versus placebo.

    In plain wordsIn adults with overweight or obesity, CagriSema caused slightly more side effects than placebo in a pooled analysis.

    Peptide
    Cagrilintide
    Outcome
    IncreaseAdverse events with CagriSema
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    Both treatments showed modest but statistically significant increases in adverse events.
    1 context sentence
    Summary · context
    Eligible randomized controlled trials (RCTs) assessed Cagrilintide monotherapy or CagriSema versus placebo.

    In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.

  6. 10HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with overweight or obesity, CagriSema reduced body weight by a mean difference of -5.98% versus placebo in the meta-analysis.

    In plain wordsIn adults with overweight or obesity, the CagriSema combination reduced body weight more than placebo in pooled trials.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight change (percent)
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Mean difference in body weight
    −5.98%
    CagriSema vs placebo

    Source sentences

    Summary
    CagriSema significantly reduced body weight (MD: -5.98%; MD: -4.68 kg), waist circumference (MD: -10.91 cm), systolic blood pressure, and HbA1c.
    2 context sentences
    Summary · context
    Cagrilintide, a once-weekly amylin receptor agonist, and its fixed-dose combination with semaglutide (CagriSema) represent novel therapeutic approaches.
    Summary · context
    Four RCTs encompassing 5425 participants were included.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  7. 11HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with overweight or obesity, CagriSema reduced body weight by a mean difference of -4.68 kg versus placebo in the meta-analysis.

    In plain wordsIn adults with overweight or obesity, the CagriSema combination reduced body weight in kilograms more than placebo in pooled trials.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight change (kg)
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Mean difference in body weight
    −4.68 kg
    CagriSema vs placebo

    Source sentences

    Summary
    CagriSema significantly reduced body weight (MD: -5.98%; MD: -4.68 kg), waist circumference (MD: -10.91 cm), systolic blood pressure, and HbA1c.
    2 context sentences
    Summary · context
    Cagrilintide, a once-weekly amylin receptor agonist, and its fixed-dose combination with semaglutide (CagriSema) represent novel therapeutic approaches.
    Summary · context
    Four RCTs encompassing 5425 participants were included.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  8. 12HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with overweight or obesity, CagriSema reduced waist circumference by a mean difference of -10.91 cm versus placebo in the meta-analysis.

    In plain wordsIn adults with overweight or obesity, the CagriSema combination reduced waist size more than placebo in pooled trials.

    Peptide
    Semaglutide
    Outcome
    DecreaseWaist circumference
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Mean difference in waist circumference
    −10.91 cm
    CagriSema vs placebo

    Source sentences

    Summary
    CagriSema significantly reduced body weight (MD: -5.98%; MD: -4.68 kg), waist circumference (MD: -10.91 cm), systolic blood pressure, and HbA1c.
    2 context sentences
    Summary · context
    Cagrilintide, a once-weekly amylin receptor agonist, and its fixed-dose combination with semaglutide (CagriSema) represent novel therapeutic approaches.
    Summary · context
    Four RCTs encompassing 5425 participants were included.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  9. 13HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with overweight or obesity, CagriSema significantly reduced systolic blood pressure versus placebo in the meta-analysis.

    In plain wordsIn adults with overweight or obesity, the CagriSema combination lowered the top blood pressure number more than placebo in pooled trials.

    Peptide
    Semaglutide
    Outcome
    DecreaseSystolic blood pressure
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular

    Source sentences

    Summary
    CagriSema significantly reduced body weight (MD: -5.98%; MD: -4.68 kg), waist circumference (MD: -10.91 cm), systolic blood pressure, and HbA1c.
    2 context sentences
    Summary · context
    Cagrilintide, a once-weekly amylin receptor agonist, and its fixed-dose combination with semaglutide (CagriSema) represent novel therapeutic approaches.
    Summary · context
    Four RCTs encompassing 5425 participants were included.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  10. 14HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with overweight or obesity, CagriSema significantly reduced HbA1c versus placebo in the meta-analysis.

    In plain wordsIn adults with overweight or obesity, the CagriSema combination lowered HbA1c more than placebo in pooled trials.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    CagriSema significantly reduced body weight (MD: -5.98%; MD: -4.68 kg), waist circumference (MD: -10.91 cm), systolic blood pressure, and HbA1c.
    2 context sentences
    Summary · context
    Cagrilintide, a once-weekly amylin receptor agonist, and its fixed-dose combination with semaglutide (CagriSema) represent novel therapeutic approaches.
    Summary · context
    Four RCTs encompassing 5425 participants were included.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  11. 15HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome

    In adults with overweight or obesity, CagriSema showed a modest but statistically significant increase in adverse events versus placebo in the meta-analysis, as did cagrilintide monotherapy.

    In plain wordsIn adults with overweight or obesity, side effects were modestly but significantly more common with the CagriSema combination than with placebo.

    Peptide
    Semaglutide
    Outcome
    IncreaseAdverse events
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Adverse events · Metabolic and weight

    Source sentences

    Summary
    Both treatments showed modest but statistically significant increases in adverse events.
    2 context sentences
    Summary · context
    Cagrilintide, a once-weekly amylin receptor agonist, and its fixed-dose combination with semaglutide (CagriSema) represent novel therapeutic approaches.
    Summary · context
    Four RCTs encompassing 5425 participants were included.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 3 to 38Current

    28 Oct 2026, 02:04 UTC

    The same notice was added 36 times, first on 9 Oct 2026, 18:17 UTC. The status did not change between them.

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.